データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
57-22-7CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1OGWKCGZFUXNPDA-CFWMRBGOSA-N57-22-7DTXSID1032278CHEMBL499458化学的特性solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
毒性LD50 2.2 mg/kg(マウス,静注).
解説ビンクリスチン,融点218~220 ℃.[α]25D+17°(ジクロロエタン).pKa 5.0,7.4(DMF).硫酸塩は分解点273~281 ℃.水,メタノールに易溶.λmax 220,255,296 nm(エタノール).急性白血病,悪性リンパ腫治療薬として使用される.森北出版「化学辞典(第2版)
用途急性白血病,悪性リンパ腫治療薬として使用される.
説明A complex dimeric alkaloid isolated from Vinca minor, this base has the structure given above based upon chemical and spectroscopic data. It resembles Vinblastine in its pharmacological action. Depending on the dosage, it causes either thrombocytosis with no effect upon the leucocytes, or thrombocytopenia accompanied by peucopenia in rats. Thrombocytosis persists even after prolonged treatment with drugs given in the correct dosage.
来歴Vinblastine and vincristine were extracted from vinca, and researchers found that they are the main ingredient of vinca which have antitumor activity. This is an accidental harvest by hard work and inspiration during scientific research process. It was firstly reported as an important discovery by Annals of the New York Academy of Sciences, and one report was published by Robert Noble and Charles Thomas Beer . They demonstrated that vinblastine can cause severe leukopenia. In 1963, vincristine (trade name, Oncovin) developed by Eli Lilly was approved by the US FDA, it provided a good choice for tumor chemotherapy program and gradually became the essential tumor chemotherapy drugs. At the early stages of the study, vinblastine and vincristine are directly extracted from the vinca, but the cost is high, and the extraction efficiency is low . Especially the specific chiral monomer compounds with biological activity are difficult to obtain. In the following years, the researchers used genetic engineering, biosynthesis, chemical synthesis, and other technical methods to explore and optimize the production process of vinblastine drugs. In particular, the rise of asymmetric synthesis provides a more economical choice for the synthesis of vinblastine compounds and increases productivity to more than 22% . At the same time, the pharmaceutical dosage forms were developed from the beginning as simple sulfate injection to liposomal preparations and nanoparticle preparations, which improve the efficacy, reduce adverse reactions, and play better antitumor effect.
使用Antineoplastic[Note—Graphic formula same as for Vinblastine Sulfate, except that R is CHO].
一般的な説明A white crystalline solid. Melting point 218°C. Used as an antineoplastic.
現在のフィルター条件では反応記録がありません。
読み込み中…